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Abstract
Background:  subcutaneous  immunoglobulin  (scIg)
therapy is an alternative to intravenous immunoglobu-
lin (IVIg) therapy. 
Methods: we evaluated the efficacy and safety of the
scIg  Vivaglobinﾮ (formerly  known  as  beriglobinﾮ
sc) under real-life conditions in a post-marketing ob-
servational study in 82 patients with primary or sec-
ondary antibody deficiencies. Health-related quality of
life (HRQol) was evaluated in a subset of 30 patients
previously  treated  with  IVIg  (including  11  children
<14 years) using the short form 36 (sf-36) for pa-
tients ≥ 14 years of age (adults) and the child Health
Questionnaire  -  Parental  form  50  (cHQ-Pf50)  for
children <14 years of age. treatment preferences were
assessed in adults. 
Results:  the  mean  serum  immunoglobulin  g  (Igg)
trough  level  during  scIg  treatment  (7.5  g/l)  was
higher than during previous IVIg treatment (6.6 g/l;
p<0.01).  the  investigators  assessed  the  efficacy  of
scIg therapy as “excellent” in 89% of patients. no
systemic  adverse  drug  reactions  were  observed.  Im-
provements by ≥5 points were observed in 5 of 8 sf-
36 subscales and in 6 of 12 cHQ-Pf50 subscales. sta-
tistically significant improvements (p≤0.05) were ob-
served for the sf-36 subscales of bodily pain, general
health  perceptions,  and  vitality  (adults),  and  for  the
cHQ-Pf50  subscales  of  general  health  perceptions,
parental  impact  -  time,  parental  impact  -  emotional,
and  family  activities  (children).  Patients  preferred
scIg  over  IVIg  therapy  (92%)  and  home  therapy
over therapy at the clinic/physician (83%). 
Conclusion: this study confirms that therapy with Vi-
vaglobinﾮ at home is effective, safe, well tolerated, and
improves quality of life in patients with antibody defi-
ciency.
Key  words:  antibody  deficiency,  subcutaneous  im-
munoglobulin therapy, quality of life, children, adults
Abbreviations: cHQ-Pf50:  child  Health  Question-
naire – Parental form 50; HRQol: health-related qual-
ity of life; Igg: immunoglobulin g; IVIg: intravenous
immunoglobulin; scIg: subcutaneous immunoglobu-
lin; sf-36: HRQol questionnaire short form 36
IntRoductIon
Primary  antibody  deficiencies  belong  to  the  wide
range of primary immune deficiency diseases caused
by intrinsic or genetic defects in the immune system
[1, 2]. they comprise a range of inherited disorders
that are characterized by defects in antibody produc-
tion and/or function. common variable immunodefi-
ciency, which is the most common of the more severe
primary immunodeficiencies, is associated with recur-
rent  or  chronic  infections  of  the  respiratory  tract
(>95%) and the gastrointestinal tract (approximately
50%), as well as with autoimmune phenomena (20%
to  30%),  splenomegaly  (approximately  30%),  non-
caseating granulomas (approximately 10%), and malig-
nancies [3, 4].
Patients suffering from primary antibody deficien-
cies require lifelong regular immunoglobulin infusions
[2,  5].  nowadays,  subcutaneous  immunoglobulin
(scIg) infusions are used as an alternative to intra-
venous  immunoglobulin  (IVIg)  administration  in
adults  and  children  with  primary  or  secondary  anti-
body deficiencies [6, 7]. scIg infusions were shown
to be efficacious, safe, and well tolerated [8]. they are
also appreciated by adults and children for their ease
of administration [8, 9]. few systemic adverse reac-
tions have been reported during scIg infusions, indi-
cating a favourable safety profile compared to intra-
venous  or  intramuscular  administration  of  im-
munoglobulin [10, 11]. the average serum levels at-
tained during scIg therapy are comparable to those
attained during IVIg therapy, but with reduced oscil-
lations between consecutive infusions [9, 12, 13].
Home-based scIg treatment is convenient because
fewer visits to the clinic or physician are required than
with  IVIg  therapy,  which  is  not  licensed  as  home
treatment in germany. the safe and easy-to-use scIg
infusion  technique  [14]  supports  scIg  home  treat-
ment as an alternative to IVIg therapy [15, 16].
a possible increase in quality of life is another im-
portant aspect of home-based scIg treatment. only
limited data on self-reported outcomes in health-relat-
ed quality of life (HRQol) in adults and children with
primary  antibody  deficiencies  receiving  replacement
therapy  are  available  [17,  18,  19,  20,  21].  However,
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2. Hoffmann_Umbruchvorlage  14.06.10  20:27  Seite 238where  available,  these  data  revealed  significant  im-
provements in quality of life in patients switching from
IVIg therapy at the hospital to scIg therapy at home.
the  first  immunoglobulin  g  (Igg)  preparation
specifically approved for subcutaneous administration,
Vivaglobinﾮ (formerly known as beriglobinﾮ sc; csl
behring,  Marburg,  germany),  was  licensed  in  ger-
many in december 2002 and in the usa in January
2006. scIg infusions have also been used in scandi-
navian countries for nearly 20 years in the treatment of
antibody deficiencies, and home-based scIg therapy
is now the standard of care in many countries [22]. 
the  aims  of  this  post-marketing  observational
study were to evaluate the efficacy and safety of scIg
replacement therapy with Vivaglobinﾮ under real-life
conditions in adults and children with primary or sec-
ondary antibody deficiencies, and to describe HRQol
in this population. 
MEtHods
study dEsIgn
this  was  a  prospective,  observational,  multicentre
study  conducted  in  germany.  the  study  design  in-
volved 7 visits to the clinic or physician during the 9-
month study period (visits 1 to 4 were monthly, subse-
quent visits were every 2 months). for patients previ-
ously treated with IVIg, baseline data obtained before
the first administration of Vivaglobinﾮ at visit 1, re-
flecting  conditions  during  prior  IVIg  therapy,  were
compared to data obtained at the follow-up (visit 7)
after 9 months of treatment with Vivaglobinﾮ.
Patients with primary or secondary antibody defi-
ciencies were eligible for the study, with no age limit
specified. Efficacy and safety evaluations were based
on all 82 patients enrolled in the study. HRQol was
evaluated  only  in  patients  who  had  been  on  IVIg
therapy before enrolment. If patients had missing data
for specific endpoints, they were excluded from the
analyses of those endpoints.
tREatMEnt
Vivaglobinﾮ was  used  as  a  ready-to-use  pasteurized
liquid containing polyvalent human Igg at a concen-
tration of 160 mg/ml (16%). subcutaneous infusions
were administered using small, battery-driven syringe
drivers as described by gardulf et al. [9].
a weekly scIg dose of 100 to 200 mg/kg body
weight is considered sufficient to achieve serum Igg
levels within the normal range in adults and children
[11, 23]. In patients who received IVIg therapy before
enrolment, the monthly IVIg dose was divided by 4
to  calculate  a  corresponding  weekly  dose  for  scIg
therapy. Patients who received weekly scIg infusions
before  enrolment  continued  with  the  same  weekly
dose.
all patients and parents or guardians were trained
in  the  subcutaneous  administration  of  Vivaglobinﾮ
during 4 to 6 training sessions at the clinic or physi-
cian’s office. Patients had to demonstrate skill, knowl-
edge, and confidence in scIg administration before
the  therapy  could  be  self-administered  at  home; 
parents or guardians gave the infusions to their chil-
dren or supervised their children’s self-administration
of scIg. 
study outcoMEs
the efficacy and safety analysis included all enrolled
patients with available data. the HRQol analysis in-
cluded all patients who had been receiving IVIg ther-
apy before enrolment and who had completed their
HRQol questionnaire at baseline within 2 weeks of
starting Vivaglobinﾮ administration and at the final as-
sessment (visit 7). Missing data for an entire assess-
ment (i.e., missing forms) were not imputed.
sERuM Igg tRougH lEVEls
serum Igg trough levels measured within 2 months
before study start were recorded at baseline. during
the study, blood samples were drawn for the analysis
of serum Igg trough levels. for patients previously
treated  with  IVIg,  serum  Igg  trough  levels  during
scIg therapy with Vivaglobinﾮ at visits 4 and 7 were
compared  to  trough  levels  measured  during  IVIg
treatment within 2 months prior to study start and 3
to 4 weeks after an IVIg infusion.
EffIcacy
at the final assessment scheduled after 9 months of
treatment,  the  investigator  assessed  the  outcome  of
the scIg therapy in terms of its efficacy using cate-
gories of “excellent”, “acceptable”, and “insufficient”.
In addition, the investigators assessed the feasibility of
patients learning to use the treatment as a home-based
therapy. Patients were asked how flexible they thought
the  scIg  therapy  was  compared  to  IVIg  therapy
(more, the same, or less flexibility).
HEaltH-RElatEd QualIty of lIfE (HRQol)
Patients who had previously been on IVIg therapy
completed HRQol questionnaires at study start (base-
line) and at the final assessment (follow-up). the pa-
tients or their parents or guardians gave informed con-
sent to the scientific processing of their data.
the HRQol questionnaire short form 36 (sf-36)
was used for patients older than 14 years (i.e., adoles-
cents and adults, hereafter referred to as adults). the
sf-36 consists of 35 items forming 8 subscales mea-
suring physical and mental health (table 1) [24, 25].
the 1-year comparison of health item was excluded
because the study assessment period was less than 1
year. Higher scores indicate a better HRQol (possible
scores: 0 to 100).
the child Health Questionnaire - Parental form 50
(cHQ-Pf50) was used for patients younger than 14
years and was answered by their parents or guardians
[26]. this questionnaire focuses on the physical and
psychosocial functioning and well-being of the child
and the child’s family. It consists of 50 items forming
12 subscales (table 2) [19]. as for the sf-36 question-
naire, the global item change in health was not used
because of the 1-year recall period. Higher scores indi-
cate a better HRQol (possible scores: 0 to 100).
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status on a visual-analogue scale ranging from 0 (worst
imaginable health state) to 100 (best imaginable health
state).
at follow-up, adults assessed their treatment prefer-
ences  regarding  the  route  of  administration  (scIg,
IVIg, or no preference) and the location of Igg thera-
py (at home, at the clinic/physician, or no preference).
safEty
any signs of scIg-related systemic adverse reactions
were documented. at each visit, blood samples were
taken  for  laboratory  tests  (haematology  and  chem-
istry),  and  a  physical  examination  was  performed.
safety data were analysed descriptively for all patients
who had received at least 1 infusion of Vivaglobinﾮ.
statIstIcal analysIs
categorical data are presented using frequencies (num-
ber,  percentage),  and  continuous  data  are  presented
using mean, standard deviation (sd) or standard error
(sE), median, and maximum and minimum values. for
comparison of data obtained at baseline and at the fi-
nal visit, the student’s paired t-test was used. statistical
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Table 1. scales of the HRQol questionnaire short form 36.
SF-36 scale Number of items Description
Physical health
Physical functioning 10 limitations in various physical activities
Role physical 4 Problems with work or other daily activities as a result of physical health
bodily pain 2 limitations due to pain
general health perceptions 5 Evaluation of personal health
Mental health
Vitality 4 Energy and fatigue
social functioning 2 Interference with normal social activities due to physical and emotional 
problems
Role emotional 3 Problems with work or other daily activities as a result of emotional 
problems
Mental health 5 Psychological distress and well-being
Table 2. scales of the child Health Questionnaire - Parental form 50.
CHQ-PF50 scale Number of items Description
Physical
Physical functioning 6 limitations in physical activities such as walking, bathing, and 
strenuous sports
Role physical 2 limitations in school-related activities and activities with friends as 
a result of physical health
bodily pain 2 Intensity and frequency of general pain or discomfort
general health perceptions 6 Perception of overall health status
Psychological
Role emotional/behavioural 3 limitations in school, work, or activities with friends as a result of 
emotional or behavioural problems
behaviour 6 ability to get along with others and behavioural problems including 
aggression, delinquency, hyperactivity or impulsivity, and social 
withdrawal
Mental health 5 both negative and positive states including anxiety, depression, and 
positive effect
self esteem 6 satisfaction with school and athletic ability, looks or appearance, 
ability to get along with others and family, and life overall
Parental impact
Parental impact - emotional 3 distress and worry experienced by parent regarding child’s 
condition
Parental impact - time 3 limitations in personal time experienced by parent due to child’s 
conditions
Family
family activities 6 limitations and interruptions in usual family activities and family 
tension as a result of child’s health
family cohesion 1 ability of family members to get along with one another
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processed using sas, version 8.2 (sas Institute Inc.,
cary,  nc,  usa)  and  Microsoftﾮ office  Excel  2003
(Microsoft corporation, Redmond, wa, usa).
REsults
study PoPulatIons and tREatMEnt
a total of 82 patients were enrolled in the study at 24
sites in germany. the mean age was 34 years (range: 1
to  74  years),  and  17  subjects  were  younger  than  14
years (table 3). the mean weight was 62 kg (range: 10
to 117 kg). the most frequent diagnoses were com-
mon variable immunodeficiency (54%) and X-linked
agammaglobulinaemia (16%). nine patients (11%) had
secondary immune deficiencies, with chronic lympho-
cytic  leukaemia  (4  patients)  and  non-Hodgkin  lym-
phomas (3 patients) being the most frequent underly-
ing diseases. the majority of the patients (73%) had
previously received IVIg, 15% had received scIg, 4%
intramuscular and 7% no immunoglobulin treatment. 
overall, the 82 patients received a total of approxi-
mately 3500 scIg infusions during the study. for the
406 infusions that were documented at the 7 study vis-
its, the median number of infusions sites was 2 (range:
1 to 6). the most common application sites were the
abdomen (84%) and the thigh (10%); in 5% of the
cases, both of these sites were used. the mean (ﾱsd)
dose was 91 (ﾱ31) mg/kg/week, the mean (ﾱsd) dos-
ing volume per week was 35 (ﾱ15) ml, and the mean
(ﾱsd) infusion rate was 12 (ﾱ6) ml/hour. after the
first visit, most infusions (87%) were self-administered
or administered by a parent or guardian.
a total of 22 patients (22 adults, no child) discon-
tinued the study prematurely. for 8 patients, the rea-
son  for  discontinuation  was  given  (1  patient  each):
hospitalization  for  stem  cell  transplantation;  no  fur-
ther Igg treatment necessary; decision of patient; ad-
verse drug reaction; overall end of study reached be-
fore scheduled final visit of the patient; progression of
underlying malignant disease; patient could not cope
with subcutaneous treatment; and psychiatric disease.
a total of 48 patients completed the HRQol ques-
tionnaire at baseline. Eighteen of these patients (13
adults and 5 children) were excluded from the HRQol
analysis because they had not received IVIg prior to
study start (4 patients), or they completed the baseline
HRQol questionnaire more than 2 weeks after their
first Vivaglobinﾮ administration (8 patients), or they
did not complete the follow-up HRQol questionnaire
at the final visit (6 patients). thus, HRQol was evalu-
ated for 30 patients (19 adults and 11 children; table
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Table 3. demographic and medical data.
Population
Variable Efficacy + safety HRQoL a
number of patients enrolled, n 82 48 b
number of evaluable patients, n (%) 82 (100%) 30 (100%)
sex, n (%)
Male 34 (41%) 19 (63%)
female 46 (56%) 11 (37%)
Missing 2 (2%) 0
age (years), mean (range) 34 (1-74) 30 (3-74)
age group, n (%)
< 14 years 17 (21%) 11 (37%)
≥ 14 years 65 (79%) 19 (63%)
diagnosis, n (%)
common variable immunodeficiency 44 (54%) 11 (37%)
X-linked agammaglobulinaemia (bruton disease) 13 (16%) 9 (30%)
severe combined immunodeficiency 4 (5%) 1 (3%)
Igg subclass deficiency 4 (5%) 1 (3%)
other congenital hypo- or agammaglobulinaemia 5 (6%) 2 (7%)
secondary immunodeficiency  9 (11%) 5 (17%)
Missing 3 (4%) 1 (3%)
Prior treatment with immunoglobulins, n (%)
Intravenous infusions 60 (73%) 30 (100%)
Intramuscular infusions 3 (4%) 0
subcutaneous infusions 12 (15%) 0
none 6 (7%) 0
Missing 1 (1%) 0
a the HRQol population is a subpopulation of the efficacy + safety population.
b number of patients who completed the baseline HRQol questionnaire.
2. Hoffmann_Umbruchvorlage  14.06.10  20:27  Seite 2413). for the analysis of treatment preferences, all adults
who answered the questions on treatment preferences
at the final visit were considered (24 patients).
outcoMEs
Serum IgG trough levels
for 20 patients who had been on IVIg before Viva-
globinﾮ treatment, serum Igg trough levels were avail-
able which fulfilled both of the following conditions:
(i) measured within 2 months before study start and
(ii) measured 3 to 4 weeks after an IVIg infusion. the
mean serum Igg trough level before study start was
6.6 g/l, as compared to 7.5 g/l at visit 4 (100 days af-
ter  baseline)  and  at  visit  7  (290  days  after  baseline; 
fig. 1). the difference between the mean Igg trough
level during IVIg treatment before study start com-
pared to Igg trough levels with scIg at visit 4 and
visit 7 was statistically significant (p<0.01 at both eval-
uations), while the mean monthly Igg dose was not
statistically different between IVIg (0.39 g/kg body
weight; monthly administration) and scIg (0.37 g/kg
body  weight;  administered  in  4  weekly  doses).  the
mean (ﾱsE) serum Igg trough level for all patients
with  available  data  was  7.1  (ﾱ0.3)  g/l  at  visit  4
(n=55) and 7.2 (ﾱ0.3) g/l at visit 7 (n=54).
EffIcacy
Efficacy of the scIg therapy was evaluated by the in-
vestigators in 61 of the 82 patients treated. the scIg
therapy was assessed as “excellent” in 89% of patients
(table 4). In 10% of patients, the scIg therapy was
assessed as “acceptable”, and in only 1 patient was the
scIg therapy assessed as “insufficient”. the investi-
gators considered the administration of scIg therapy
as “easy to learn and well feasible” in 82% of patients,
as “learnable and feasible” in 15% of patients, and as
“too hard to learn as home therapy” in only 3% of pa-
tients (table 4). of the 44 patients who documented
their opinions on the scIg treatment, 86% reported
that the scIg therapy gave more flexibility than IVIg
therapy, 9% stated it was the same, and 5% stated that
the scIg therapy provided less flexibility (table 4).
HEaltH-RElatEd QualIty of lIfE
In adults, the mean sf-36 scores increased by at least 5
points between baseline and follow-up in 5 out of 8
scales,  including  all  scales  of  the  category  physical
health (fig. 2a) and the scale of vitality in the category
mental  health  (fig.  2b).  the  improvement  between
baseline and follow-up scores was statistically signifi-
cant for bodily pain (p=0.02), general health percep-
tions (p=0.05), and vitality (p=0.05).
the  cHQ-Pf50  questionnaire  was  completed  by
caregivers for children younger than 14 years. Increases
of at least 5 points in the mean scores were observed
between baseline and follow-up in 6 out of 12 scales,
including physical functioning, role physical, and gen-
eral health perceptions in the physical category (fig.
3a), both scales in the parental impact category, and the
scale family activities in the family category (fig. 3c). In
the psychological category, generally no difference be-
tween baseline and follow-up was observed, except for
a slight decrease in the behaviour scale, which was not
statistically  significant  (fig.  3b).  the  difference  be-
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Fig. 1. serum Igg trough levels (means and standard errors).
for this analysis, 20 patients were considered who had pre-
study serum Igg concentrations which fulfilled both of the
following conditions: (i) measured within 2 months before
study start and (ii) measured 3 to 4 weeks after an IVIg infu-
sion. on average, visit 4 was 100 days and visit 7 was 290
days after baseline.
Table 4. Efficacy outcomes and preferences regarding Igg therapy at follow-up.
Efficacy outcomes Number (%) of patients
Assessment of SCIG therapy by investigator (N = 61)
Excellent 54 (89)
acceptable 6 (10)
Insufficient 1 (2)
Final assessment of therapy by investigator (N = 61)
Easy to learn and well feasible 50 (82)
learnable and feasible 9 (15)
too hard to learn as home therapy 2 (3)
Final assessment of therapy by patient (N = 44)
gives more flexibility than IVIg 38 (86)
gives the same flexibility as IVIg 4 (9)
gives less flexibility than IVIg 2 (5)
2. Hoffmann_Umbruchvorlage  14.06.10  20:27  Seite 242tween  baseline  and  follow-up  scores  was  statistically
significant  for  general  health  perceptions  (p=0.04),
parental impact - emotional (p=0.03), parental impact -
time (p=0.02), and family activities (p=0.02).
the mean health status score (maximum: 100) in
adults increased from 56 at baseline (n=19) to 69 at
follow-up  (n=11);  in  children,  the  score  increased
from 65 at baseline (n=11) to 78 at follow-up (n=11).
However, the differences were not statistically signifi-
cant.
at follow-up, 92% of adults (22 patients) stated a
preference for scIg over IVIg therapy and 83% (20
patients) preferred home therapy over therapy at the
clinic/physician. only 1 patient preferred Igg therapy
in  the  clinic/physician  setting.  two  patients  had  no
preferences regarding the route of Igg administration
and 3 patients had no preference regarding location.
safEty
during the course of the study, only 2 adverse drug
reactions  (local  tissue  reactions)  were  reported  by  2
adult patients, neither of which was a severe systemic
adverse event. one patient discontinued treatment be-
cause of the adverse event (reddening, swelling, local
hyperthermia, impaired motility). no clinically relevant
changes from baseline were observed in any of the
serum chemistry or haematology parameters, or in any
of the physical examination findings. 
dIscussIon
the current study evaluated the efficacy and safety of
scIg  replacement  therapy  with  Vivaglobinﾮ under
real-life  conditions  and  described  self-reported
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Fig. 2. sf-36 scores for adults (≥14 years) in the HRQol subpopulation at baseline (visit 1) and follow-up (visit 7). Mean and
standard error data are shown (n=19, except for the scales general health perceptions and role emotional: n=18). a score of 0
indicates the worst possible health state and 100 the best possible health state. * statistically significant difference between base-
line and follow-up (p≤0.05). a) Physical health subscales. b) Mental health subscales.
fig.  3.  cHQ-Pf50  scores  for  children  <14  years  in  the
HRQol subpopulation at baseline (visit 1) and follow-up (vis-
it 7). Mean and standard error data are shown (n=11, except
for the scale self esteem: n=10). a score of 0 indicates the
worst possible health state and 100 the best possible health
state. * statistically significant difference between baseline and
follow-up  (p≤0.05).  a)  Physical  subscales.  b)  Psychological
subscales. c) Parental impact and family subscales.
a b
a b
c
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cies. 
Vivaglobinﾮ therapy at doses equivalent to the pre-
vious IVIg dose resulted in mean Igg trough levels
that were significantly higher than those during IVIg
treatment (7.5 g/l vs. 6.6 g/l; p<0.01), confirming
the  previously  reported  beneficial  effect  of  scIg
therapy  in  terms  of  normalized  or  increased  serum
Igg trough levels [8, 9, 11, 12, 15], which is consid-
ered  a  contributing  factor  towards  improving  health
and vitality [27, 28].
the  investigators’  assessment  of  the  efficacy  of
scIg  therapy  with  Vivaglobinﾮ was  “excellent”  in
89% of patients. In addition, the investigators assessed
the  administration  of  Vivaglobinﾮ as  “easy  to  learn
and well feasible” in 82% of patients, and 86% of pa-
tients reported that scIg therapy gave more flexibility
than  IVIg  therapy.  the  high  treatment  satisfaction
with  scIg  therapy  using  Vivaglobinﾮ concurs  with
earlier  studies  investigating  switches  from  IVIg  to
scIg [31, 32].
the HRQol evaluation generally revealed clear re-
sults in favour of scIg therapy with Vivaglobinﾮ, es-
pecially in the categories physical health (adults and
children) and parental impact (children). confirming
results with Vivaglobinﾮ therapy in clinical Phase III
studies [19, 21], significant improvements with home-
based scIg treatment under real-life conditions were
observed for the adults’ evaluation of general health
perceptions and vitality, as well as the parents’ percep-
tion  of  the  overall  health  status  of  their  child,  the
emotional distress and limitations on personal time for
the  parents,  and  the  limitations  on  family  activities.
Improvements in bodily pain for adults (p=0.02) have
not been reported before. In contrast to the previous
studies  with  Vivaglobinﾮ,  no  improvement  in  the
cHQ-Pf50  subscale  role  emotional/behaviour  was
found; the mean score at baseline was 91 and did not
change at follow-up. In a recent study, fasth and nys-
tr￶m evaluated the parents’ and children’s perspective
of HRQol with scIg treatment in 12 children and
saw significant improvements in family activities from
the parents’ perspective [18]. the current study con-
firms this trend. fasth and nystr￶m also reported im-
provements  in  mental  health,  for  which  only  an  in-
significant improvement was seen in the current study,
and in the item change in health, which was not as-
sessed  in  the  current  study.  Interestingly,  fasth  and
nystr￶m  reported  no  significant  improvements  for
parental impact [18]. overall, scIg therapy at home
offers increased HRQol comparable to that of age-
matched  healthy  controls  [19,  27,  32].  It  should  be
noted that the improvements in HRQol observed in
this study could be a result of switching from IVIg to
scIg, from hospital-based to home-based treatment,
or a combination of both.
assessments  of  treatment  preferences  revealed  a
clear trend in favour of scIg therapy and home treat-
ment.  this  trend  concurs  with  earlier  observations
with Vivaglobinﾮ where a clear majority of children or
parents (88%) and adults (82%) preferred scIg thera-
py [19].
In the current study, no severe systemic side-effects
were observed during scIg therapy with Vivaglobinﾮ,
confirming the favourable safety profile in comparison
to IVIg therapy reported previously [9, 29]. specifi-
cally,  the  low  incidence  of  side-effects  with  scIg
therapy in children is important because side-effects
are common with IVIg therapy in children and can
cause significant morbidity [30]. overall, scIg thera-
py with Vivaglobinﾮ was safe and well tolerated in pa-
tients with primary or secondary antibody deficiencies.
In conclusion, our results show that scIg therapy
with  Vivaglobinﾮ under  real-life  conditions  is  effec-
tive, safe, and well tolerated in patients with primary
or secondary antibody deficiencies. the subcutaneous
route allows self-administration at home and therefore
enables a more independent lifestyle than with IVIg
therapy. Patients in this study had a clear preference
for scIg therapy at home, which is reflected in signif-
icant improvements in HRQol.
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